CGEM vs CGTX

Cullinan Therapeutics, Inc. vs Cognition Therapeutics, Inc. — Valuation Comparison 2026

CGEM

Biotechnology
Cullinan Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$15.36
Last close
Models
7/13
Active
VS

CGTX

Biotechnology
Cognition Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
36
LOW
Price
$1.19
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType CGEM Fair ValueCGEM Upside CGTX Fair ValueCGTX Upside
Bayesian DCF Intrinsic $4.78 -68.9% $0.51 -57.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.71 -88.9%
Dynamic NAV Asset-Based $6.17 -59.8% $0.64 -45.8%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGEM vs CGTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGEM vs CGTX — Which Stock Is More Undervalued?

CGEM scores higher with a 4.4/10 quality rating vs CGTX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cullinan Therapeutics, Inc. (CGEM) and Cognition Therapeutics, Inc. (CGTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGEM currently trades at $15.36 with a QOC of 4.4/10, while CGTX trades at $1.19 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).